Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

How I (Diagnose and) Treat Myeloid / Lymphoid Neoplasms with Tyrosine Kinase Gene Fusions

Andreas Reiter, Georgia Metzgeroth, Nicholas C.P. Cross

Blood blood.2023022417.

https://doi.org/10.1182/blood.2023022417

Published: 2024

Journal Articles

Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study

Kathy Dominy, Matthew Salmon, Richard Szydlo, Chloe Hayden, Helen E White, Mary Alikian, Dragana Milojkovic, Mhairi Copland, Letizia Foroni, Nicholas C.P. Cross, Richard E Clark, Jane F. Apperley

Blood (2022) 140 (Supplement 1): 9631–9632.

https://doi.org/10.1182/blood-2022-170375

Published: 2022

Journal Articles

Response and Resistance to Cladribine in Patients with Advanced Systemic Mastocytosis: A Registry-Based Analysis

Johannes Lübke, Nicole Naumann, Sebastian Kreil, Georgia Metzgeroth, Hans-Peter Horny, Karl Sotlar, Nicholas C.P. Cross, Alice Fabarius, Peter Valent, Wolf-Karsten Hofmann, Juliana Schwaab, Andreas Reiter

Blood (2022) 140 (Supplement 1): 3970–3971.

https://doi.org/10.1182/blood-2022-163650

Published: 2022

Journal Articles

Karyosequencing: Integrating Genome-Wide and Targeted Sequencing for Comprehensive Diagnosis of Lymphoproliferative Disorders

James Peter Stewart, Louise Harewood, Shambhavi Srivastava, Jana Gazdova, Manisha Maurya, Sirintra Nakjang, Elizabeth Hodges, Laura Chiecchio, Nicholas C.P. Cross, Matthew W Jenner, Mark Catherwood, Sarra Ryan, Anthony V. Moorman, Nikos Darzentas, David Gonzalez

Blood (2021) 138 (Supplement 1): 272.

https://doi.org/10.1182/blood-2021-152258

Published: 2021

Journal Articles

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

Jenny Byrne, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Adam J. Mead, MD PhD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Gavin Campbell, FRCP,FRCPath, Ian Amott, Andrew Goringe, Earnest Heartin, Evangelia Dimitriadou, MD, Ian Pamphlett, Siamak Arami, MD MRCP, FRCPath, Pratap Neelakantan, Rebecca Frewin, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Hugues De Lavallade, Nicholas C.P. Cross, Michael Thompson

Blood (2019) 134 (Supplement_1): 3434.

https://doi.org/10.1182/blood-2019-122893

Published: 2019

Journal Articles

A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients

Mohamad Jawhar, Juliana Schwaab, Nicole Naumann, Georgia Metzgeroth, MD, Hans-Peter Horny, Karl Sotlar, Manja Meggendorfer, PhD, Torsten Haferlach, MD, Nicholas C.P. Cross, Alice Fabarius, Wolf-Karsten Hofmann, Peter Valent, Andreas Reiter, MD

Blood (2018) 132 (Supplement 1): 349.

https://doi.org/10.1182/blood-2018-99-115804

Published: 2018

Journal Articles

Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study

Jennifer O'Sullivan, MB BCh BAO, Angela Hamblin, MD PhD, Anesh Panchal, BSc, MSc, Christina Yap, MSci, PhD CStat, Sonia Fox, BSc, Samah Alimam, DHSC, MD, Helene Marie-Pierre Dreau, Kieran Howard, Pauline Ware, Samantha Baker, Nicholas C.P. Cross, Mary Frances McMullin, MD, Claire N. Harrison, MD DM, FRCP, PRCPath, Adam J. Mead, MD PhD

Blood (2018) 132 (Supplement 1): 1784.

https://doi.org/10.1182/blood-2018-99-118220

Published: 2018

Journal Articles

KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

Blood (2018) 132 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2018-99-115895

Published: 2018

Journal Articles

The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia

Dragana Milojkovic, MBBS, PhD, Richard E. Clark, Jennifer L Byrne, Brian J.P Huntly, Manoj Raghavan, Farooq A Wandroo, Sahra Ali, Belinda Austen, Jacqueline Ryan, Karsten Friedrich, Nicholas C.P. Cross, PhD, Adam J Mead, MD PhD

Blood (2017) 130 (Supplement 1): 2892.

https://doi.org/10.1182/blood.V130.Suppl_1.2892.2892

Published: 2017

Journal Articles

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Blood (2017) 130 (Supplement 1): 2916.

https://doi.org/10.1182/blood.V130.Suppl_1.2916.2916

Published: 2017

Journal Articles

Sample Exchange to Standardize Molecular Monitoring for CML: The EUTOS Experience

Martin C. Müller, MD, Christian Dietz, PhD, Giuseppe Saglio, MD PhD, Francois-Xavier Mahon, MD PhD, Fabrizio Pane, MD, Andreas Hochhaus, MD, Nicholas C.P. Cross, PhD

Blood (2017) 130 (Supplement 1): 2874.

https://doi.org/10.1182/blood.V130.Suppl_1.2874.2874

Published: 2017

Journal Articles

Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors

Mohamad Jawhar, MD, Juliana Schwaab, MD, Manja Meggendorfer, PhD, Nicole Naumann, Hans-Peter Horny, MD, Karl Sotlar, MD, Torsten Haferlach, MD, Karla Schmitt, MD, Alice Fabarius, PhD, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Georgia Metzgeroth, MD, Andreas Reiter, MD

Blood (2016) 128 (22): 3109.

https://doi.org/10.1182/blood.V128.22.3109.3109

Published: 2016

Journal Articles

Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms

Andreas Reiter, MD, Gunay Ahmadova, MD, Mohamad Jawhar, MD, Andres Virchis, MD, Tim Somervaille, MDPhD, Mark Williams, MD, Bernd Schönberger, MD, Rebecca Frewin, FRCPath, MRCP, MBBS, BSc, Philipp J. Jost, MD, Annett Maschke, MD, Peter Keller, MD, Torsten Haferlach, MD, Nicole Naumann, Juliana Schwaab, MD, Alice Fabarius, PhD, Wolf-Karsten Hofmann, MD, Claudia Haferlach, MD, Nicholas C.P. Cross, PhD, Georgia Metzgeroth, MD

Blood (2016) 128 (22): 3114.

https://doi.org/10.1182/blood.V128.22.3114.3114

Published: 2016

Journal Articles

The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis

Richard T. Silver, Ariella Barel, Elena Lascu, BA,MA, Ellen K. Ritchie, MD, Gail J. Roboz, MD, Paul Christos, Attilio Orazi, MD, Duane C Hassane, PhD, Wayne Tam, MD PhD, Nicholas C.P. Cross, PhD

Blood (2016) 128 (22): 944.

https://doi.org/10.1182/blood.V128.22.944.944

Published: 2016

Journal Articles

Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis

Mohamad Jawhar, MD, Juliana Schwaab, MD, Nicole Naumann, Sebastian Kluger, Hans-Peter Horny, MD, Karl Sotlar, MD, Torsten Haferlach, MD, Georgia Metzgeroth, MD, Alice Fabarius, PhD, Peter Valent, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Manja Meggendorfer, PhD, Andreas Reiter, MD

Blood (2016) 128 (22): 945.

https://doi.org/10.1182/blood.V128.22.945.945

Published: 2016

Journal Articles

Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis

Nicole Naumann, Mohamad Jawhar, MD, Juliana Schwaab, MD, Georgia Metzgeroth, MD, Henning D Popp, MD, Nada Khaled, MD, Hans-Peter Horny, MD, Karl Sotlar, MD, Peter Valent, MD, Claudia Haferlach, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, Prof, MD, Manja Meggendorfer, PhD, Nicholas C.P. Cross, PhD, Wolf-Karsten Hofmann, MD, Andreas Reiter, MD, Alice Fabarius, PhD

Blood (2016) 128 (22): 947.

https://doi.org/10.1182/blood.V128.22.947.947

Published: 2016

Journal Articles

Inhibitory Effects of Midostaurin and Blu-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis

Mohamad Jawhar, MD, Nicole Naumann, Sebastian Kluger, Juliana Schwaab, MD, Georgia Metzgeroth, MD, Erica K. Evans, PhD, Alexandra Gardino, PhD, Christoph Lengauer, PhD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Alice Fabarius, PhD, Andreas Reiter, MD

Blood (2016) 128 (22): 1964.

https://doi.org/10.1182/blood.V128.22.1964.1964

Published: 2016

Journal Articles

Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes

Sebastian Kreil, MD PhD, Lionel Adès, MD PhD, Martin Bommer, MD, Frank Stegelmann, MD, Mark E Ethell, MBBChir, MA, FRCP, FRCPath, Anna Lubking, MD, Peter Martin, MD, Ekkehard Eigendorff, MD, Wolf-Karsten Hofmann, MD, Nicholas C.P. Cross, PhD, Andreas Hochhaus, MD, Andreas Reiter, MD

Blood (2015) 126 (23): 2812.

https://doi.org/10.1182/blood.V126.23.2812.2812

Published: 2015

Journal Articles

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Delphine Rea, MD PhD, Gianantonio Rosti, MD, Nicholas C.P. Cross, PhD, Andrzej Hellman, MD PhD, Dietger Niederwieser, MD, Ester Pungolino, MD, Franca Falzetti, MD, Patrizia Pregno, MD, Ester Maria Orlandi, MD, Antonio Medina Almeida, Arpad Illes, MD PhD, Cristalina Fernandez, Luca Dezzani, Angela Pellegrino, Chiara Costantini, Claudia Walasek, Giuseppe Saglio, Juan Luis Steegmann, MD, Michele Baccarani

Blood (2015) 126 (23): 4040.

https://doi.org/10.1182/blood.V126.23.4040.4040

Published: 2015

Journal Articles

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Blood (2015) 126 (23): 4054.

https://doi.org/10.1182/blood.V126.23.4054.4054

Published: 2015

NARROW

How I (Diagnose and) Treat Myeloid / Lymphoid Neoplasms with Tyrosine Kinase Gene Fusions

Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study

Response and Resistance to Cladribine in Patients with Advanced Systemic Mastocytosis: A Registry-Based Analysis

Karyosequencing: Integrating Genome-Wide and Targeted Sequencing for Comprehensive Diagnosis of Lymphoproliferative Disorders

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients

Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study

KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Sample Exchange to Standardize Molecular Monitoring for CML: The EUTOS Experience

Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors

Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms

The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis

Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis

Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis

Inhibitory Effects of Midostaurin and Blu-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis

Limited Efficacy of Ponatinib in Myeloproliferative Neoplasms Associated with FGFR1 Fusion Genes

Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase

Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only